Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target to $36.00 ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

So, let’s take a look at the Value Grade for all of our stocks. Amphastar Pharmaceuticals, Inc. stock has a Value Grade of B. Takeda Pharmaceutical Company Limited stock has a Value Grade of B.

The format is potentially more convenient than traditional glucagon kits from the likes of Fresenius Kabi and Amphastar, but Xeris has struggled to penetrate the vast opportunity. Xeris said it ...

Amphastar Pharmaceuticals, Inc. stock has a Value Grade of B. Royalty Pharma plc stock has a Value Grade of B. Takeda Pharmaceutical Company Limited stock has a Value Grade of B. Viatris Inc. stock ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...